Europe Clinical Trials Market Size, Share and Trends Analysis Report 2022-2030 by Study Design (Interventional, Observational, Expanded Access) and Phase (Phase I, Phase II, Phase III, Phase IV) –


DUBLIN–(BUSINESS WIRE)–The “Report analyzing the size, share and trends of the clinical trials market in Europe by study design (interventional, observational, expanded access), by phase (phase I, phase II, phase III, Phase IV), by Region and Segment Forecast, 2022-2030″ report has been added to from offer.

The size of the clinical trials market in Europe is expected to reach USD 20.2 billion by 2030. The market is expected to grow at a CAGR of 5.7% from 2022 to 2030.

One of the major market drivers is the increase in technological advancements for clinical trials. Growing adoption of new technologies such as artificial intelligence, big data analytics, blockchain, clinical trial payments, and patient engagement solutions, among others, has significantly contributed to the growth of the market . The COVID-19 pandemic has enhanced the adoption of virtual clinical trials in the region. Hence, increasing adoption of new technologies is likely to drive the growth of the market.

The demand for personalized medicines has improved significantly in the region thanks to significant funding for research on personalized therapies by the European Commission. The aim of various countries in Europe is to collaborate on research and health policy to accelerate the adoption of personalized medicine with the formation of the International Consortium for Personalized Medicine, which brings together research funders health and policy groups. Such activities are likely to promote the growth of the market. The region suffers from increasing disease variation and prevalence. A significant number of people in the region suffer from chronic and rare diseases.

For example, the European Commission indicates that approximately 5,000 to 8,000 distinct rare diseases affect approximately 6 to 8% of the European population, ie between 27 and 36 million. Thus, the high burden of rare diseases is likely to increase the demand for researchers to develop therapies for rare diseases.

Rising costs associated with research studies have increased the demand for ORCs in the region to conduct clinical trials. The partnership agreement between pharmaceutical companies and CROs is likely to promote market growth.

Europe has been one of the regions hardest hit by the COVID-19 pandemic, with public organizations in the region providing significant research funding to boost the development of COVID-19 vaccines and diagnostics . For example, in June 2020, the French President pledged to invest $679 million to support the development of vaccines against COVID-19.

Due to the pandemic, several research centers have been closed due to the nationwide lockdown put in place by government authorities, through which several clinical trial organizations have opted for in silico trials and virtual clinical trials to speed up the process. of research. Such actions had benefited the growth of the market.

Highlights of the Europe Clinical Trials Market Report

  • The phase I trials segment is expected to experience a remarkable growth rate of 6.1% during the forecast period. This can be attributed to large R&D expenditures by public and private organizations to support new research

  • The interventional study design segment held the largest market share of 78.6% in 2021 due to the higher precision offered by these studies, compared to other clinical study designs

  • European countries such as Germany and UK lead the revenue share as they have a large pool of patients and the presence of advanced medical infrastructure.

Market dynamics

Market Driver Analysis

  • Increasing adoption of new technologies in clinical research

  • Towards personalized medicine

  • Increasing variation and prevalence of diseases

  • CRO market growth

Market Restriction Analysis

  • Regulation in the development of new drugs

  • Price pressure

Clinical trials market in Europe: analysis tools

  • Porter’s Five Forces Analysis

  • Pestel analysis

  • Analysis of major transactions and strategic alliances

Analysis of the total number of clinical trial studies conducted, by country

Cost Allocation Analysis for CROs

  • Percentage of outsourced versus in-house clinical trial categories

  • Cost Breakdown Analysis for CROs by Phases I, II and III

  • Cost Breakdown Analysis for CROs by Phases I, II and III FOR Germany

Covid-19 impact analysis

Company Profiles

  • IQVIA Holdings, Inc.,

  • Parexel International Corporation

  • PPD, Inc.

  • Syneos Health

  • Eli Lilly and company

  • Novo Nordisk A/S

  • Pfizer, Inc.

  • Dr. Notghi Contract Research GmbH

  • Charitable research organization GmbH

  • Janssen Global Services, LLC

  • KFGN

  • Clarity

  • Invisio Clinical Studies Consulting GmbH

For more information about this report visit

Source link

Comments are closed.